Innoviva, Inc. (INVA)
NASDAQ: INVA · IEX Real-Time Price · USD
15.26
+0.27 (1.80%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Innoviva Employees
Innoviva had 112 employees on December 31, 2023. The number of employees increased by 11 or 10.89% compared to the previous year.
Employees
112
Change (1Y)
11
Growth (1Y)
10.89%
Revenue / Employee
$2,771,991
Profits / Employee
$1,604,661
Market Cap
964.85M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 112 | 11 | 10.89% |
Dec 31, 2022 | 101 | 96 | 1,920.00% |
Dec 31, 2021 | 5 | 0 | - |
Dec 31, 2020 | 5 | -1 | -16.67% |
Dec 31, 2019 | 6 | 0 | - |
Dec 31, 2018 | 6 | -6 | -50.00% |
Dec 31, 2017 | 12 | -2 | -14.29% |
Dec 31, 2016 | 14 | 1 | 7.69% |
Dec 31, 2015 | 13 | 3 | 30.00% |
Dec 31, 2014 | 10 | -231 | -95.85% |
Dec 31, 2013 | 241 | 15 | 6.64% |
Dec 31, 2012 | 226 | 4 | 1.80% |
Dec 31, 2011 | 222 | 29 | 15.03% |
Dec 31, 2010 | 193 | -1 | -0.52% |
Dec 31, 2009 | 194 | 3 | 1.57% |
Dec 31, 2008 | 191 | -120 | -38.59% |
Dec 31, 2007 | 311 | 26 | 9.12% |
Dec 31, 2006 | 285 | 15 | 5.56% |
Dec 31, 2005 | 270 | 24 | 9.76% |
Dec 31, 2004 | 246 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
INVA News
- 3 days ago - Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 - Business Wire
- 7 weeks ago - Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 2 months ago - Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - 10 stocks you can bet on being inflation-proof - Market Watch
- 6 months ago - Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress - Business Wire
- 6 months ago - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea - Business Wire
- 7 months ago - Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023 - Business Wire
- 7 months ago - Innoviva to Participate in the Cantor Global Healthcare Conference - Business Wire